← All tickers

Is REPL Worth Buying in 2026?

Replimune Group, Inc.

STOCK BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Updated 2026-08-16

Here’s whether Replimune Group, Inc. (REPL) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.

🟢
Bullish

Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+15.75% over 10 days); strong 1-year return of +194.1%; 3-month momentum positive (+203.7%). Currently 4.7% off its 52-week high. Score: +6/7.

Ready to act on this? 📈 Trade on Webull

REPL is in a confirmed uptrend, trading above both its 50-day ($10.70) and 200-day ($8.16) moving averages. An RSI of 66.1 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +194.1% compares to +20.4% for SPY (beat the market by 173.7%).

$10,000 invested 1 year ago → $29,411 today
vs. S&P 500 (SPY) — same period beat market by 173.7%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

✓Above 200-day MA ($8.16)
✓Above 50-day MA ($10.70)
✓RSI(14) neutral zone (30–70) — currently 66.1
✓Positive return (+194.1%)
✓Within 10% of period high (−4.7%)
Period Range $14.97
$1.50 $15.71
RSI (14) 66.1
0 · OversoldOverbought · 100

Key Metrics

Price$14.97
Period Return+194.1%
Period High$15.71
Period Low$1.50
Drawdown−4.7%
MA-50$10.70
MA-200$8.16
RSI (14)66.1
Avg Volume (30d)6.4M
vs. SPYbeat by 173.7%
Return Rank#64 of 1252

Trade REPL

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers